Multiparametric genomic assays for breast cancer: Time for the next generation?

Adam M. Brufsky, Nancy E. Davidson

Research output: Contribution to journalArticlepeer-review

Abstract

The Breast Cancer Index appears to perform better than the 21-gene recurrence score in predicting 10-year disease-free survival in postmenopausal women with hormone receptor-positive lymph node-negative early-stage breast cancer. This may have implications for clinical use of first-generation versus second-generation multiparametric genomic assays.

Original languageEnglish (US)
Pages (from-to)4963-4965
Number of pages3
JournalClinical Cancer Research
Volume22
Issue number20
DOIs
StatePublished - Oct 15 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Multiparametric genomic assays for breast cancer: Time for the next generation?'. Together they form a unique fingerprint.

Cite this